drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
An off-the-shelf, gene-engineered CD19-directed chimeric antigen receptor (CAR) T-cell product. Binding to CD19 on B-lineage cells triggers CAR signaling (CD3ζ with co-stimulation), T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxicity, leading to depletion of CD19+ malignant B cells (e.g., B-ALL, B-cell lymphomas).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Gene‑engineered T cells expressing a CD19‑specific chimeric antigen receptor bind CD19 on B‑lineage cells, activating CAR signaling (CD3ζ with co‑stimulation) to trigger T‑cell activation, cytokine release, and perforin/granzyme‑mediated cytotoxicity, resulting in depletion of CD19+ malignant B cells.
drug_name
4SCAR19U universal CD19-specific CAR T cells
nct_id_drug_ref
NCT05995015